Patients undegoing cardiac implantable electronical device implantation while being treated with antiplatelet therapy: consensus recommmendations
| In patients on single antiplatelet therapy (aspirin or clopidogrel) for secondary prevention, it is recommended to continue aspirin during CIED implantations. |
| In patients on DAPT (i.e. aspirin plus clopidogrel or other P2Y12 agent) requiring device surgery within 4 weeks of BMS or within 6 months of DES implantation (within 3 months with new-generation DES), it is recommended to continue both AP agents. |
| In patients on DAPT, it should be considered to defer elective device implantations until DAPT is no longer necessary. |
| In patients on DAPT after ACS requiring device surgery >4 weeks after BMS implantation or >6 months after DES (>3 months after new-generation DES), it should be considered to stop the P2Y12 inhibitor for 5–7 days before surgery, but consider resuming a P2Y12 inhibitor as soon as possible after the procedure. A multidisciplinary approach for the individual patient is recommended. |
| In patients on single antiplatelet therapy (aspirin or clopidogrel) for secondary prevention, it is recommended to continue aspirin during CIED implantations. |
| In patients on DAPT (i.e. aspirin plus clopidogrel or other P2Y12 agent) requiring device surgery within 4 weeks of BMS or within 6 months of DES implantation (within 3 months with new-generation DES), it is recommended to continue both AP agents. |
| In patients on DAPT, it should be considered to defer elective device implantations until DAPT is no longer necessary. |
| In patients on DAPT after ACS requiring device surgery >4 weeks after BMS implantation or >6 months after DES (>3 months after new-generation DES), it should be considered to stop the P2Y12 inhibitor for 5–7 days before surgery, but consider resuming a P2Y12 inhibitor as soon as possible after the procedure. A multidisciplinary approach for the individual patient is recommended. |
Patients undegoing cardiac implantable electronical device implantation while being treated with antiplatelet therapy: consensus recommmendations
| In patients on single antiplatelet therapy (aspirin or clopidogrel) for secondary prevention, it is recommended to continue aspirin during CIED implantations. |
| In patients on DAPT (i.e. aspirin plus clopidogrel or other P2Y12 agent) requiring device surgery within 4 weeks of BMS or within 6 months of DES implantation (within 3 months with new-generation DES), it is recommended to continue both AP agents. |
| In patients on DAPT, it should be considered to defer elective device implantations until DAPT is no longer necessary. |
| In patients on DAPT after ACS requiring device surgery >4 weeks after BMS implantation or >6 months after DES (>3 months after new-generation DES), it should be considered to stop the P2Y12 inhibitor for 5–7 days before surgery, but consider resuming a P2Y12 inhibitor as soon as possible after the procedure. A multidisciplinary approach for the individual patient is recommended. |
| In patients on single antiplatelet therapy (aspirin or clopidogrel) for secondary prevention, it is recommended to continue aspirin during CIED implantations. |
| In patients on DAPT (i.e. aspirin plus clopidogrel or other P2Y12 agent) requiring device surgery within 4 weeks of BMS or within 6 months of DES implantation (within 3 months with new-generation DES), it is recommended to continue both AP agents. |
| In patients on DAPT, it should be considered to defer elective device implantations until DAPT is no longer necessary. |
| In patients on DAPT after ACS requiring device surgery >4 weeks after BMS implantation or >6 months after DES (>3 months after new-generation DES), it should be considered to stop the P2Y12 inhibitor for 5–7 days before surgery, but consider resuming a P2Y12 inhibitor as soon as possible after the procedure. A multidisciplinary approach for the individual patient is recommended. |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
